CASE REPORT

Pleural effusion as the initial extramedullary manifestation of Acute Myeloid Leukemia [version 1; referees: 3 approved]

José Nieves-Nieves¹, Luis Hernandez-Vazquez², Dev Boodoosingh¹,
Ricardo Fernández-Gonzalez¹, Rosángela Fernández-Medero¹,
José Adorno-Fontánez¹, Edgardo Adorno-Fontánez¹, José Lozada-Costas³

¹Pulmonary Medicine, San Juan City Hospital, San Juan, Puerto Rico
²Internal Medicine, San Juan City Hospital, San Juan, Puerto Rico
³Hematology-Oncology Medicine, San Juan City Hospital, San Juan, Puerto Rico

Abstract

Leukemias rarely debut by pleural involvement as the first manifestation of the hematologic malignancy. This complication is most commonly seen in solid tumors such as carcinomas of the breast, lung, gastrointestinal tract and lymphomas. We present a case of a 66 year old male who presented with a pleural leukemic infiltration of his undiagnosed Acute Myeloid Leukemia that was not a complication of the disease extension, but the acute presentation of the illness. Progressive shortness of breath for two weeks, cough, clear sputum and weight loss were the initial complaints. Serum dyscrasia suggested a hematologic abnormality. A chest x-ray performed demonstrated a buildup of fluid with layering in the left pleural cavity. Diagnostic thoracentesis suggested an exudative etiology with cytology remarkable for 62% leukemic myeloblast. The diagnosis was confirmed by bone marrow biopsy with expression of the antigens CD 34+ and CD13+, with unfavorable cytogenetic prognosis and a trisomy 21 chromosomal defect. Chemotherapy was initiated, though no remission achieved with induction chemotherapy. Complications and disease progression precludes in the patient’s death. Although rare, due to the unusual presentation of the disease, this case clearly demonstrates the importance of biochemical analysis and cytopathology specimens obtained in pleural fluid.

Open Peer Review

Referee Status: 🟢 🟢 🟢

version 1
published 30 Oct 2012

† Sharon Savage, National Cancer Institute, National Institutes of Health (NIH) USA
2 Stephen Nimer, Memorial Sloan-Kettering Cancer Center USA
3 Adlette Inati, Children’s Center for Cancer and Blood Diseases, Rafik Hariri University Hospital Lebanon

Discuss this article

Comments (0)
Introduction
Acute Myelogenous Leukemia (AML) is a group of hematogenous neoplasms characterized by clonal proliferation of myeloid precursors with a reduced capacity to differentiate into more mature cellular elements. As a result, there is an accumulation of leukemic blasts or immature forms in the bone marrow, peripheral blood, and occasionally in other tissues, with a variable reduction in the production of normal red blood cells, platelets, and mature granulocytes. The increased production of malignant cells, along with a reduction in these mature elements, result in a variety of systemic consequences including anemia, bleeding, and an increased risk of infection. Less than 1 percent of patients present with prominent extramedullary disease. These extramedullary manifestations can manifest simultaneously with, or precede, bone marrow involvement. Sites of isolated expression include bone, peristomeum, soft tissues, and lymph nodes, and less commonly the orbit, intestine, mediastinum, epidural region, uterus, and ovary. To our knowledge this is one of the few reported cases of pleural effusion as the initial manifestation of AML.

Case report
A 66 year old man with a long-standing history of mild to moderate asthma and arterial hypertension was evaluated for a worsening productive cough of clear sputum, dyspnea, wheezing, and unintentional weight loss of approximately thirty pounds. The patient denied fever, chills, hemoptysis, night sweats, chest pain, or exposure to sick contacts. His medications were frequent use of short acting β-agonist with minimal resolution of symptoms.

On physical examination, the patient was alert but in mild respiratory distress, afebrile without hemodynamic compromise. The cardiac examination was normal; pulmonary examination revealed diffuse decreased breath sounds, inspiratory crackles, and dullness to percussion, decreased fremitus and egophony in up to two thirds of the left lung field. There was no use of accessory muscles and oxygen saturation was 90% with the patient breathing ambient air. Neither lymphadenopathy nor organomegaly was palpated. CBC was abnormal for hemoglobin 8.1 g/dL, platelet 60,000/µL, leukocyte count 87000/µL with 64% blast (Table 1). Arterial blood gases were pH 7.402, PCO₂ 38.3 mmHg, and PO₂ 67 mmHg; oxygen saturation was 89% without supplemental oxygen.

Table 1. Complete blood count with differential.

<table>
<thead>
<tr>
<th>Laboratory studies</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobin</td>
<td>8.1 g/dL (81 g/L)</td>
</tr>
<tr>
<td>Platelets</td>
<td>60,000/µL (60 x 10⁹/L)</td>
</tr>
<tr>
<td>Leukocyte</td>
<td>87,000/µL (87 x 10⁹/L)</td>
</tr>
<tr>
<td>Blast</td>
<td>64%</td>
</tr>
<tr>
<td>Neutrophils</td>
<td>10%</td>
</tr>
<tr>
<td>Lymphocytes</td>
<td>14%</td>
</tr>
</tbody>
</table>

A hematologic malignancy was suggestive due to the serum dyscrasia. Chest radiograph showed a large free flowing left pleural effusion (Figure 1). A diagnostic and therapeutic thoracentesis was performed with removal of approximately 1 liter of fluid. The symptoms resolved and biochemical analysis established an exudative etiology (Table 2). The cytopathology specimen obtained from the pleural fluid was positive for blast cells with 62% leukemic myeloblast. AML was confirmed by bone marrow biopsy with expression of the antigens CD 34+ and CD 13+ (Figure 2) with intermediate to unfavorable cytogenetic prognosis (Table 3).

A karyotypic abnormality of Trisomy 21 was revealed through cytogenetic studies (Figure 3), which is the second most common chromosomal defect in AML. The patient was treated with Idarubicin...
combined with Cytarabine for the recently discovered AML and there was no re-accumulation of the pleural fluid. However, bone marrow aspiration was repeated to assess response to chemotherapy and he still presented with 62% of blasts cells. A new cycle of chemotherapy was started with Mitoxantrone, Etoposide and Cytarabine but only a partial response was obtained. Despite the therapeutic regimen, due to the severity of the disease and the poor cytogenetic prognosis, the patient’s condition deteriorated. In view of no significant response to therapy and dismal prognosis, supportive measures and palliative care was provided and eventually the patient died due to complications associated to AML.

**Discussion**

Physicians dealing with the diagnostic workup of pleural effusions rarely discover an underlying hematologic malignancy\(^1\). AML generally presents with symptoms related to complications of pancytopenia. Most patients have more subtle evidence of bone marrow involvement for weeks, or perhaps months, before the diagnosis can be made. Despite the pancytopenia, and/or coagulopathy, it is unusual for leukemias, either acute or chronic, to manifest with malignant pleural effusions as the initial presentation\(^3\)–\(^5\). Usually this abnormal amount of fluid collection is a complication more commonly seen in solid tumors and lymphomas\(^1\).

Our patient presented with AML and pulmonary involvement with signs and symptoms secondary to the pleural effusion itself rather than with classical appearance of the acute myeloid leukemia. An unusual case where neither the complications of the hematologic dyscrasia such as bleeding and recurrent infections, nor the physical findings of a swollen spleen, liver, or lymph nodes were the primary target organs that would lead to a presumptive diagnosis. This demonstrates the importance of the biochemical analysis and the cytopathology specimens obtained in pleural fluid since an early detection of any determined disease could guide effective therapy\(^6\)–\(^7\). AML in this particular case, and prompt treatment could undoubtedly contribute in avoiding complications associated with the condition; an essential factor for improving quality of life. For this reason chest physicians should be aware of all possible pulmonary manifestations of hematologic malignancies.

**Consent**

Written informed consent for publication of clinical details and clinical images was obtained from the relative of the patient.

**Author contributions**

Authors have contributed to the literature review, drafting of the manuscript, revisions of the manuscript and have agreed to the final content.

**Competing interests**

No competing interests have been disclosed.

**Grant information**

The author(s) declared that no grants were involved in supporting this work.

---

### Table 2. Pleural fluid description. Ratio of the pleural fluid lactate dehydrogenase and protein to serum lactate dehydrogenase and protein (Light’s criteria meeting exudative etiology).

<table>
<thead>
<tr>
<th>Color</th>
<th>Protein</th>
<th>LDH</th>
<th>Glucose</th>
<th>pH</th>
<th>PF(<em>{protein}/)Serum(</em>{protein})</th>
<th>PF(<em>{LDH}/)Serum(</em>{LDH})</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dark yellow</td>
<td>5.4</td>
<td>537</td>
<td>88</td>
<td>7.5</td>
<td>0.74</td>
<td>1.09</td>
</tr>
</tbody>
</table>

### Table 3. Flow cytometry differential of leukocyte population demonstrating low immunophenotypic values of lymphocytes and granulocytes which demonstrates an unfavorable cytogenetic prognosis.

<table>
<thead>
<tr>
<th>Flow cytometry differential (% of Total cells)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Lymphocytes</td>
<td>2</td>
</tr>
<tr>
<td>B-cells</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Kappa</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Lambda</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Kappa:Lamba Ratio</td>
<td>1</td>
</tr>
<tr>
<td>T-cells</td>
<td>1</td>
</tr>
<tr>
<td>CD4</td>
<td>1</td>
</tr>
<tr>
<td>CD8</td>
<td>1</td>
</tr>
<tr>
<td>CD4:CD8 Ratio</td>
<td>1.6</td>
</tr>
<tr>
<td>CD3+CD56+</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Natural killer cells</td>
<td>1</td>
</tr>
<tr>
<td>Monocytes</td>
<td>7</td>
</tr>
<tr>
<td>Granulocytes</td>
<td>20</td>
</tr>
<tr>
<td>CD34-Positive blasts</td>
<td>62</td>
</tr>
<tr>
<td>Plasma cells</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Viability</td>
<td>99</td>
</tr>
</tbody>
</table>

**Figure 3.** Trisomy 21 as the sole acquired karyotypic abnormality in our patient with acute myeloid leukemia (arrow).
References

Open Peer Review

Current Referee Status: ✔ ✔ ✔

Version 1

Referee Report 29 November 2012
doi:10.5256/f1000research.216.r352

Adlette Inati
Division of Pediatric Hematology and Oncology, Children's Center for Cancer and Blood Diseases, Rafik Hariri University Hospital, Beirut, Lebanon

The authors report a case of pleural effusion as an initial presentation of Acute Myeloid Leukemia (AML) in an adult patient with no physical exam findings suggestive of leukemia and or malignancy.

The authors corroborated the exudative nature of this symptomatic pleural effusion by flow cytometric analysis for CD34+ and CD13+ antigens and supported their diagnosis by bone marrow studies and cytogenetic analysis which showed a trisomy 21 pattern. While a chemotherapeutic regimen of Cytarabine and Idarubicine inhibited further progression and re accumulation of the pleural effusion, the patient's condition deteriorated leading to his death. Given the dismal nature of the patient’s AML prognosis, hematologists need to be aware of this atypical and rare AML presentation. More importantly, pulmonary physicians should acquaint themselves with this clinical scenario because such patients present first to them and not to hematologists.

Pleural effusion has been reported in association with solid tumors and sometimes as their presenting sign. A multivariate analysis by Faiz et al., Leukemia Lymphoma (2012) between 1997 and 2007 showed that 111 patients with acute leukemias had pleural effusions and the median overall survival in these patients was shorter than those with absence of pleural effusions. Other studies revealed rare occurrences of pleural effusion in AML patients.

The authors need to highlight salient features of previously reported patients and compare them with their patient hoping to find predictive factors for development of such rare clinical scenarios and define better treatments.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Competing Interests: No competing interests were disclosed.

Referee Report 22 November 2012
doi:10.5256/f1000research.216.r351

Stephen Nimer
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
This article points out an unusual clinical presentation of acute myeloid leukemia (AML) that illustrates the heterogeneity of presentations of extramedullary disease.

While the diagnosis was clear at the onset, the patient had 64% circulating blasts and the pleural effusion was unusual and required evaluation. As monocyte subtypes of AML have a propensity for tissue invasion and the core binding factor (CBF) leukemia can be associated with granule cystic sarcomas, a bit more information on the immunophenotype of the AML would have been helpful in assessing this case. Also, given the many molecular markers that define the prognosis of AML patients, more details on any molecular studies that were done, or could have been done, would be helpful.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

**Competing Interests:** No competing interests were disclosed.

---

**Referee Report 21 November 2012**

**doi:** 10.5256/f1000research.216.r350

Sharon Savage  
Division of Cancer Epidemiology & Genetics, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD, USA

This case report describes a case of acute myeloid leukemia (AML) that presented with a large pleural effusion. This unusual presentation is important to recognize when evaluating patients with pleural effusions. This particular case report illustrates the importance of a cytopathology evaluation.

The report itself would benefit from an updated reference on chromosomal abnormalities in AML, and it would also be helpful to know the doses of the chemotherapeutic agents and if the patient was treated on a clinical trial for newly diagnosed AML.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

**Competing Interests:** No competing interests were disclosed.